Historie von Umsatz, Gewinn und Cashflow aus den offiziellen Geschäftsberichten.
Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates in four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to individual, employer group risk-based and fee-based, BlueCard, Medicare, Medicaid, and FEP members; health products; a broad array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, and supplemental health insurance benefits.
Interaktive Charts und vollständige Abschlüsse ansehen → Bewertungsmodell (DCF) →
| Gewinn- und Verlustrechnung | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gesamtumsatz | $201.1B | $199.1B | $176.8B | $171.3B | $156.6B | $138.6B | $121.9B | $104.2B | $92.1B | $90.0B | $85.0B | $79.2B | $73.9B | $71.1B | $61.5B | $60.8B | $58.8B | $61.6B | $62.5B | $61.4B | $57.0B |
| Bruttoergebnis | — | $50.9B | $49.2B | $47.0B | $40.0B | $36.0B | $33.8B | $22.4B | $20.2B | $17.8B | $18.1B | $18.1B | $17.1B | $14.9B | $13.3B | $13.2B | $13.9B | $14.7B | $14.2B | $15.0B | $14.5B |
| Bruttomarge % | — | 25.6% | 27.9% | 27.4% | 25.5% | 26.0% | 27.8% | 21.5% | 21.9% | 19.8% | 21.3% | 22.9% | 23.1% | 20.9% | 21.6% | 21.6% | 23.6% | 23.8% | 22.8% | 24.4% | 25.4% |
| Betriebsergebnis (EBIT) | — | $8.1B | $8.9B | $8.7B | $8.5B | $8.9B | $7.7B | $6.7B | $5.8B | $5.0B | $5.4B | $5.4B | $5.1B | $4.7B | $4.4B | $4.5B | $4.8B | $4.9B | $5.0B | $6.0B | $5.4B |
| Operative Marge % | — | 4.1% | 5.0% | 5.1% | 5.4% | 6.5% | 6.3% | 6.5% | 6.3% | 5.5% | 6.4% | 6.8% | 6.9% | 6.6% | 7.2% | 7.4% | 8.2% | 8.0% | 7.9% | 9.7% | 9.4% |
| Jahresüberschuss | $5.0B | $5.7B | $6.0B | $6.0B | $5.9B | $6.1B | $4.6B | $4.8B | $3.8B | $3.8B | $2.5B | $2.6B | $2.6B | $2.7B | $2.7B | $2.6B | $2.9B | $4.7B | $2.5B | $3.3B | $3.1B |
| Nettomarge % | 2.5% | 2.8% | 3.4% | 3.5% | 3.8% | 4.4% | 3.8% | 4.6% | 4.1% | 4.3% | 2.9% | 3.2% | 3.5% | 3.7% | 4.3% | 4.3% | 4.9% | 7.7% | 4.0% | 5.5% | 5.4% |
| EBITDA | — | $9.7B | $10.5B | $10.5B | $10.1B | $10.0B | $8.2B | $7.9B | $7.0B | $5.6B | $6.2B | $6.2B | $5.8B | $5.4B | $5.1B | $5.0B | $5.4B | $8.4B | $4.2B | $6.3B | $5.9B |
| Ergebnis je Aktie (EPS) | $22.45 | $25.53 | $25.68 | $25.22 | $24.28 | $24.73 | $17.98 | $18.47 | $14.75 | $14.35 | $9.21 | $9.38 | $8.99 | $8.74 | $8.18 | $7.25 | $6.94 | $9.82 | $4.75 | $5.56 | $4.82 |
| Ausstehende Aktien (Mio.) | — | 222M | 233M | 237M | 243M | 247M | 254M | 260M | 254M | 268M | 268M | 273M | 286M | 304M | 325M | 365M | 416M | 483M | 524M | 602M | 642M |
Quelle: veröffentlichte Unternehmensberichte (SEC). Bitte prüfen Sie die Zahlen vor Verwendung auf SEC EDGAR.
Bilanzen, Cashflow-Rechnungen, Quartalsdaten und alle Kennzahlen finden Sie im interaktiven Viewer für ELV. /companies/us/ELV
Die Informationen auf dieser Website dienen ausschließlich Bildungs- und Informationszwecken und stellen keine Anlageberatung dar. Es werden keine Kursziele und keine Anlageurteile veröffentlicht.
About TickerBase · Data methodology & sources · Privacy · Terms